Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Polaris Global Equity Bernard Horn | “Ireland-based Jazz Pharmaceuticals announced record quarterly revenues driven by Epidiolex and Xywav. The company also received FDA approvals of two drugs and reported positive Phase 3 trial results for its potential blockbuster HER2+ cancer treatment Ziihera. These developments strengthened confidence in Jazz's growth outlook. Management highlighted a robust pipeline supporting future revenue expansion. BSD Analysis: Jazz is a specialty pharma company built on cash flow discipline rather than binary science bets. Its core franchises generate durable free cash flow that funds pipeline expansion internally. Acquisitions broaden exposure without introducing existential balance-sheet risk. Investors fixate on patent timelines and ignore commercial execution quality. Rare disease and oncology exposure supports pricing resilience. Incremental pipeline wins matter more than blockbuster dreams. Operating leverage improves as integration settles. Jazz doesn't need hype to work. This is pharma compounding through boring competence.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Polaris International Equity Bernard Horn | “Jazz Pharmaceuticals announced record quarterly revenues driven by Epidiolex and Xywav. The company also received FDA approvals for two drugs and reported positive Phase 3 trial results for its potential blockbuster HER2+ cancer treatment Ziihera. These developments significantly improved long-term growth visibility. Strong execution across both commercial and pipeline assets supported investor confidence. BSD Analysis: Jazz is a cash-generating specialty pharma company often miscast as a single-asset story. Its core franchise throws off durable free cash flow that funds pipeline expansion internally. Recent acquisitions broaden therapeutic exposure without blowing up the balance sheet. Investors worry about patent concentration more than execution quality. Commercial infrastructure is already in place, lowering incremental risk. R&D productivity matters more than headline growth. This is pharma built on cash discipline, not binary science bets. Boring pipelines still compound.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
